Information for Healthcare Professionals

abnobaVISCUM

The medicinal product abnobaVISCUM differs from other mistletoe products with regard to the following features:

Preclinical
Cytotoxic

  • abnobaVISCUM is the only product for which mistletoe lectins are detectable in the serum following subcutaneous injection.

abnobaVISCUM during chemotherapy
Cytochrome P450

  • • abnobaVISCUM is the only product for which it has been confirmed that it does not impair the activity of cytochrom P450.

Pharmaceutical

  • No oxidative change to the active substance (mistletoe extract)
    From the time of storage of the harvested material until it is filled into ampoules, abnobaVISCUM is produced using a shielding gas to exclude the oxidative changes that are identifiable from the brown staining of similar products.
  • Liposomal processing
    Natural liposomes contained in the extract explain both the good availability and good tolerability of the medicinal products.
  • Highest mistletoe lectin and viscotoxin content
    Due to the patented manufacture of the pressed juice, 75% of the plant material used is solubilised. In this way, reproducibly high concentrations of mistletoe lectins and viscotoxins are obtained in the extract. It should be stressed that both groups of ingredients are equally well extracted.
    Despite its high active substance content compared with other mistletoe products, abnobaVISCUM is very well tolerated.

Information for Healthcare Professionals

Information for Healthcare Professionals

For further information please contact us on
phone +49 (0)7233 – 7043 200
FAX     +49 (0)7233 – 7043 301
E-Mail info@abnoba.de

Choosing the type of preparation (i.e. host tree)

For further information please contact us on
phone +49 (0)7233 – 7043 200
FAX     +49 (0)7233 – 7043 301
E-Mail info@abnoba.de

How to reach optimal dosage and long-term therapy – Short Protocol

 

For further information please contact us on
phone +49 (0)7233 – 7043 200
FAX     +49 (0)7233 – 7043 301
E-Mail info@abnoba.de

Recommendations for Use

For further information please contact us on
phone +49 (0)7233 – 7043 200
FAX     +49 (0)7233 – 7043 301
E-Mail info@abnoba.de.

Adviezen voor Gebruik in het Nederlands

Рекомендации по применению на русском языке

Package Insert

  • abnobaVISCUM is available in the following sorts:
    Abietis fir
    Aceris maple
    Amygdali almond
    Betulae birch
    Crataegi hawthron
    Fraxini ash
    Mali apple
    Pini pine
    Quercus oak

     

    This package insert corresponds to the German package insert.

Information on the storage and transport

abnoba Viscum Information sheet on storage and transport 0,02mg – 20mg

abnoba Viscum Information sheet on storage and transport D6 – D30 and Betula Folium

For further information please contact us on
phone +49 (0)7233 – 7043 200
FAX     +49 (0)7233 – 7043 301
E-Mail info@abnoba.de

PROTOCOLS

Summarised protocols

The recommendations in the protocols are based on the best verifiable data and have been compiled together with oncologists, consultants and staff from the Drug Information Department at ABNOBA GmbH. For any reports not listed here, please use our Recommendations for Use or call our therapy advice service on +49 (0)7233 – 7043 200.

Endometrial carcinoma  Short protocol

For therapy recommendations beyond the scope of the Short protocol on endometrial carcinoma please use the Recommendations for use or call our therapy advice service on +49 (0)7233 – 7043 200.
We also welcome your e-mail or FAX queries and will be happy to answer them.

Bladder carcinoma  Short protocol
Colon Carcinoma  Short protocol
Bronchial Carcinoma  Short protocol
Breast Carcinoma  Short protocol
Ovarian Carcinoma  Short protocol
Carcinoma of the prostata  Short protocol
Cervial carcinoma  Short protocol

Other uses

In the reports concerned, please observe the references to the given tumour stages, the time of therapy and/or the patient’s condition.
The report recommendations are based on the best verifiable data and have been compiled together with oncologists, consultants and staff from the Drug Information Department at ABNOBA GmbH, giving particular consideration to safety of use.

Please observe that the recommendations pertain to use outside the authorised indication (OFF-LABEL USE).

Pleurodesis  Short protocol

For therapy recommendations beyond the scope of the Short protocol on pleurodesis please use the Recommendations for Use or call our therapy advice service on +49 (0)7233 – 7043 200.
We also welcome your e-mail or FAX queries and will be happy to answer them.

Please observe that the recommendations pertain to use outside the authorised indication (OFF-LABEL USE).

In Korea, the indication “pleurodesis” is an authorised indication.

Intravenous infusion  Short protocol

For therapy recommendations beyond the scope of the Short protocol on intravenous infusion please use the Recommendations for Use or call our therapy advice service on +49 (0)7233 – 7043 200.
We also welcome your e-mail or FAX queries and will be happy to answer them.

Please observe that the recommendations pertain to use outside the authorised indication (OFF-LABEL USE).

Bladder Intravesical instillation

For therapy recommendations beyond the scope of the Short protocol on intravesical instillation please use the Recommendations for use or call our therapy advice service on +49 (0)7233 – 7043 200.
We also welcome your e-mail or FAX queries and will be happy to answer them.

Please observe that the recommendations pertain to use outside the authorised indication (OFF-LABEL USE).

Intratumoural infiltration gastrointestinal tract and liver

For therapy recommendations beyond the scope of the Short protocol on intratumoural infiltration please use the Recommendations for use or call our therapy advice service on +49 (0)7233 – 7043 200.
We also welcome your e-mail or FAX queries and will be happy to answer them.

Please observe that the recommendations pertain to use outside the authorised indication (OFF-LABEL USE).

Intratumoural infiltration pancreas

For therapy recommendations beyond the scope of the Short protocol on intratumoural infiltration please use the Recommendations for use or call our therapy advice service on +49 (0)7233 – 7043 200.
We also welcome your e-mail or FAX queries and will be happy to answer them.

Please observe that the recommendations pertain to use outside the authorised indication (OFF-LABEL USE).

Publications on abnobaVISCUM

The list of publications on abnobaVISCUM is only a selection.
Please ask for publications on special subjects by fax or e-mail.

You can find an extended list of publications on
http://wissenschaft.mistel-therapie.de/index.php5?page=52&lang=1

ARTHROSIS / BETULA FOLIUM

Literature on Betula Folium I
An aqueous birch leaf extract of Betula pendula inhibits the growth and cell division of inflammatory lymphocytes
Journal of Ethnopharmacology 136 (2011) 444-451 Elsevier

Literature on Betula Folium II
Inhibition of corneal inflamation following keratoplasty by birch leaf extract
Experimental Eye Research 97 (2012) 24-30 Elsevier

For further information please contact us on
phone +49 (7233) – 7043 200
FAX     +49 (7233) – 7043 301
E-mail info@abnoba.de